HUP0300772A2 - Medicament for the immunotherapy of malignant tumours - Google Patents

Medicament for the immunotherapy of malignant tumours

Info

Publication number
HUP0300772A2
HUP0300772A2 HU0300772A HUP0300772A HUP0300772A2 HU P0300772 A2 HUP0300772 A2 HU P0300772A2 HU 0300772 A HU0300772 A HU 0300772A HU P0300772 A HUP0300772 A HU P0300772A HU P0300772 A2 HUP0300772 A2 HU P0300772A2
Authority
HU
Hungary
Prior art keywords
immunotherapy
tumor
cytokines
added
suspension
Prior art date
Application number
HU0300772A
Other languages
English (en)
Inventor
Armin Grossmann
Klaus-Dieter Rockensuess
Claudia Ulbrich
Original Assignee
Liponova Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liponova Gmbh filed Critical Liponova Gmbh
Publication of HUP0300772A2 publication Critical patent/HUP0300772A2/hu
Publication of HUP0300772A3 publication Critical patent/HUP0300772A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Tumoros betegségek immunterápiájára vagy vakcinálására szolgálógyógyszerkészítmény, mily úgy állítható elő, hogy tumoranyagotkipreparálnak, összezúzzák és tisztított sejtszuszpenzióba viszik, aszuszpenziót g-interferonnal és tokoferol-acetáttal inkubálják ésfagyasztással tumorsejtlizátummá alakítják; álhártyás bevonatból vagyteljes vérből monocitákat izolálnak, majd a dendritikus sejtekké valódifferenciálódásukat citokinekkel történő inkubációval indukálják és asejteket meg nem tapadó állapotúvá alakítják át; ezután a fentemlített lefagyasztott tumorsejtlizátum kiszámított mennyiségétfelolvasztják, antigénként a sejtszuszpenzióhoz adják, citokinokatadnak hozzá és inkubálják, majd a keletkezett érett dendritikussejteket összegyűjtik. Ó
HU0300772A 2000-07-28 2001-07-21 Medicament for the immunotherapy of malignant tumours HUP0300772A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00116362 2000-07-28
PCT/EP2001/008455 WO2002009745A1 (de) 2000-07-28 2001-07-21 Arzneimittel zur immuntherapie maligner tumoren

Publications (2)

Publication Number Publication Date
HUP0300772A2 true HUP0300772A2 (en) 2003-08-28
HUP0300772A3 HUP0300772A3 (en) 2005-11-28

Family

ID=8169380

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300772A HUP0300772A3 (en) 2000-07-28 2001-07-21 Medicament for the immunotherapy of malignant tumours

Country Status (20)

Country Link
US (2) US20030129206A1 (hu)
EP (1) EP1305041B1 (hu)
JP (1) JP2004505058A (hu)
AT (1) ATE330626T1 (hu)
AU (1) AU2001279775A1 (hu)
BG (1) BG107482A (hu)
CA (1) CA2417374A1 (hu)
CY (1) CY1105179T1 (hu)
CZ (1) CZ299669B6 (hu)
DE (1) DE50110274D1 (hu)
DK (1) DK1305041T3 (hu)
ES (1) ES2267800T3 (hu)
HK (1) HK1055562A1 (hu)
HU (1) HUP0300772A3 (hu)
NO (1) NO20030420L (hu)
PL (1) PL358675A1 (hu)
PT (1) PT1305041E (hu)
SI (1) SI1305041T1 (hu)
SK (1) SK822003A3 (hu)
WO (1) WO2002009745A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
KR20050109498A (ko) * 2003-02-20 2005-11-21 유니버시티 오브 코네티컷 헬스 센터 암 또는 전염병 치료에서 열 충격 단백질 또는알파-2-마크로글로불린을 포함하는 조성물을 사용하는 방법
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP1974742A1 (en) * 2007-03-29 2008-10-01 LipoNova AG A method for improving the manufacturing process of a tumour vaccine
CN102470167A (zh) 2009-07-02 2012-05-23 Ith免疫治疗控股公司 基于外泌体的癌症治疗
CN105807053B (zh) 2016-04-15 2019-04-02 苏州药明康德新药开发股份有限公司 一种肿瘤解离试剂在流式细胞检测中的应用
ES2908885T3 (es) 2017-07-05 2022-05-04 Vcc Medical Deutschland Gmbh Método para fabricar una vacuna tumoral

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
DE19633731A1 (de) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybridzellen zur Steigerung der Immunogenität von Tumorzellen
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
DE19812004A1 (de) * 1998-03-19 1999-09-30 Forschungszentrum Juelich Gmbh Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung
EP1064390A4 (en) * 1998-03-20 2002-06-12 Genzyme Corp IMPROVED ANTI-TUMOR IMMUNITY
CA2326739A1 (en) * 1998-04-02 1999-10-14 The Regents Of The University Of California Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature

Also Published As

Publication number Publication date
HUP0300772A3 (en) 2005-11-28
SI1305041T1 (sl) 2006-12-31
DE50110274D1 (de) 2006-08-03
CY1105179T1 (el) 2010-03-03
PL358675A1 (en) 2004-08-09
EP1305041A1 (de) 2003-05-02
JP2004505058A (ja) 2004-02-19
US20030129206A1 (en) 2003-07-10
DK1305041T3 (da) 2006-10-23
NO20030420D0 (no) 2003-01-27
EP1305041B1 (de) 2006-06-21
US20070134275A1 (en) 2007-06-14
BG107482A (bg) 2003-11-28
CZ299669B6 (cs) 2008-10-08
AU2001279775A1 (en) 2002-02-13
HK1055562A1 (en) 2004-01-16
PT1305041E (pt) 2006-09-29
ES2267800T3 (es) 2007-03-16
NO20030420L (no) 2003-01-27
CZ2003179A3 (cs) 2004-01-14
WO2002009745A1 (de) 2002-02-07
ATE330626T1 (de) 2006-07-15
SK822003A3 (en) 2004-05-04
CA2417374A1 (en) 2003-01-27

Similar Documents

Publication Publication Date Title
Chen et al. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine
KR101419711B1 (ko) 항원제시세포의 활성화 처리방법
CN102091327B (zh) 一种负载自体肿瘤相关全抗原的树突状细胞疫苗的制备方法
Shan et al. Functional modulation of the pathway between dendritic cells (DCs) and CD4+ T cells by the neuropeptide: methionine enkephalin (MENK)
Yoo et al. Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity
EP2691110B1 (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
Noori et al. Antitumor and immunomodulatory effects of salvigenin on tumor bearing mice
CN104357390A (zh) 同时高效扩增cd3+cd56+cik细胞和cd3-cd56+nk细胞的方法
Wang et al. Osthole inhibits pancreatic cancer progression by directly exerting negative effects on cancer cells and attenuating tumor-infiltrating M2 macrophages
Xu et al. Effects of cryopreservation on chimeric antigen receptor T cell functions
JP2004536615A5 (hu)
WO2019062233A1 (zh) 包含分离的重组溶瘤痘病毒和nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
US20120039917A1 (en) Immunomodulating activities
HUP0300772A2 (en) Medicament for the immunotherapy of malignant tumours
CN103570818A (zh) 肿瘤抗原性多肽及其作为肿瘤疫苗的用途
US20190216909A1 (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
CN102099035A (zh) Iap抑制剂的免疫调节
Jin et al. Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy
Li et al. The combination of Pleurotus ferulae water extract and CpG-ODN enhances the immune responses and antitumor efficacy of HPV peptides pulsed dendritic cell-based vaccine
Pan et al. Synthesized natural peptides from amphibian skin secretions increase the efficacy of a therapeutic vaccine by recruiting more T cells to the tumour site
CN108715832A (zh) 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
CN106892974A (zh) 一种基于肿瘤抗原ecm1的长肽ere1及其在肿瘤免疫治疗中的应用
Tang et al. Phosphoglycerate kinase 1‐overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti‐tumor immunity in vivo
Zhang et al. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells
CN115957306B (zh) 一种Caerin1.1/1.9联合抗CD47抗体在制备治疗黑色素瘤药物中的应用

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: LIPONOVA AG, DE

Free format text: FORMER OWNER(S): LIPONOVA GMBH., DE

FD9A Lapse of provisional protection due to non-payment of fees